DIAPH2

Across TCGA pan-cancer cohorts, DIAPH2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated DIAPH2 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher DIAPH2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DIAPH2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, UCEC, and ESCA are the cancer types where DIAPH2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.052	0.688	<.001	24	view →
UCEC	DFS	Median	III,IV	0.895	0.509	.010	24	view →
ESCA	OS	Median	All	0.337	0.709	.004	18	view →
PAAD	DFS	Median	All	0.112	0.484	.015	12	view →
KIRP	DFS	Median	All	0.277	0.867	.004	6	view →
LGG	DFS	Median	All	0.156	0.753	<.001	6	view →
HNSC	DFS	Median	All	0.229	0.555	.026	3	view →
COAD	OS	Median	II,III,IV	0.650	0.855	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

DIAPH2–BLCA (OS)

Open the BLCA breakdown →